Interim Management Statement

RNS Number : 2399R

Dechra Pharmaceuticals PLC

28 April 2009

 



Issued by Citigate Dewe Rogerson Ltd, Birmingham

Date: Tuesday, 28 April 2009

Dechra® Pharmaceuticals PLC

Interim Management Statement

Dechra Pharmaceuticals PLC ('Dechra' or the 'Group'), publishes its Interim Management Statement covering the period from 1 January 2009 to the date of this announcement.

Since the publication of the Group's Half-Yearly Financial Report, trading has continued in-line with management expectations.

In the third quarter, the pharmaceuticals division grew revenues by 24% compared to the same period last year. For the nine months to 31 March 2009 (which includes the full benefit of the VetXX acquisition), revenue was ahead of last year by 85%. Since the launch in January 2009, US revenues to date from Vetoryl stand at $1.6 million.

The services division increased revenues in the third quarter by 7.4%, although there were additional trading days this year due to the timing of Easter. Revenue for the nine months ended 31 March 2009 was 7.7% ahead of the equivalent period last year.

As announced on 27 March 2009, the Group has signed an agreement to in-licence technology to develop a novel product for the international canine and feline veterinary pharmaceutical markets. The initial fee of €0.5 million has been expensed in the year ending 30 June 2009.

Other than as noted above, there have been no material events or transactions between 1 January 2009 and the date of this announcement.

The Board remains confident that the Group will continue to make good strategic progress throughout the remainder of the financial year.

Enquiries:
Ian Page, Chief Executive	Fiona Tooley, Director
Simon Evans, Group Finance Director	Citigate Dewe Rogerson
Dechra Pharmaceuticals PLC	Tel: [phone]
Tel: [phone]	Mobile: [phone]
Mobile: [phone] (IP) or 07775 642220 (SE)
www.dechra.com
[e-mail]

Trademarks appear throughout this release in italics. Dechra and the Dechra 'D' logo are registered Trademarks of Dechra Pharmaceuticals PLC.

 

END

 

 

IMSILFVESFIDFIA